(CSTL) Castle Biosciences - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 739m USD | Total Return: 19.8% in 12m

Melanoma, Squamous-Cell, Uveal, Esophageal, Pharmacogenomic
Total Rating 43
Safety 52
Buy Signal -0.03
Diagnostics & Research
Industry Rotation: -3.4
Market Cap: 739M
Avg Turnover: 7.13M USD
ATR: 5.41%
Peers RS (IBD): 11.8
Risk 5d forecast
Volatility57.0%
Rel. Tail Risk-11.3%
Reward TTM
Sharpe Ratio0.44
Alpha14.96
Character TTM
Beta0.151
Beta Downside0.191
Drawdowns 3y
Max DD57.74%
CAGR/Max DD0.01
EPS (Earnings per Share) EPS (Earnings per Share) of CSTL over the last years for every Quarter: "2021-03": -0.17, "2021-06": -0.34, "2021-09": -0.47, "2021-12": -0.25, "2022-03": -0.97, "2022-06": -0.06, "2022-09": -0.77, "2022-12": -0.78, "2023-03": -1.1, "2023-06": -0.7, "2023-09": -0.26, "2023-12": -0.1, "2024-03": -0.09, "2024-06": 0.31, "2024-09": 0.08, "2024-12": 0.32, "2025-03": -0.9035, "2025-06": 0.15, "2025-09": -0.02, "2025-12": -0.08, "2026-03": 0,
EPS CAGR: 1.48%
EPS Trend: 50.2%
Last SUE: 1.00
Qual. Beats: 1
Revenue Revenue of CSTL over the last years for every Quarter: 2021-03: 22.813, 2021-06: 22.758, 2021-09: 23.475, 2021-12: 25.039, 2022-03: 26.852, 2022-06: 34.838, 2022-09: 37.011, 2022-12: 38.338, 2023-03: 42.037, 2023-06: 50.138, 2023-09: 61.493, 2023-12: 66.12, 2024-03: 72.974, 2024-06: 87.002, 2024-09: 85.782, 2024-12: 86.311, 2025-03: 87.988, 2025-06: 86.188, 2025-09: 83.043, 2025-12: 87.01, 2026-03: null,
Rev. CAGR: 36.82%
Rev. Trend: 93.0%
Last SUE: 1.27
Qual. Beats: 4

Warnings

Interest Coverage Ratio -342.5 is critical

Altman Z'' -0.49 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: CSTL Castle Biosciences

Castle Biosciences (NASDAQ:CSTL) is a U.S.-based molecular diagnostics firm that develops and commercializes gene-expression and spatial-omics tests aimed at improving diagnosis and risk stratification for dermatologic cancers, Barrett’s esophagus, uveal melanoma, and several mental-health disorders.

The company’s flagship assays include DecisionDx-Melanoma and DecisionDx-UM (risk-stratification for cutaneous and uveal melanoma), DecisionDx-SCC (cutaneous squamous cell carcinoma), MyPath Melanoma (diagnostic aid for ambiguous lesions), TissueCypher (spatial-omics for Barrett’s esophagus progression), and IDgenetix (pharmacogenomic guidance for major depressive disorder and related conditions). These products are sold primarily to dermatology and gastroenterology practices.

In its most recent quarter (Q4 2025), Castle reported revenue of $78.3 million, a 25 % year-over-year increase driven by higher test volumes and expanded payer contracts. Cash and short-term investments stood at $210 million, providing runway through 2028. The molecular diagnostics sector is expected to grow at a ~9 % CAGR through 2030, propelled by rising demand for personalized oncology and mental-health testing, while Medicare’s recent decision to broaden coverage for GEP assays is a key economic catalyst for Castle’s pipeline.

For a deeper dive into how Castle fits into the broader ValueRay analytics platform, you might want to explore the latest ValueRay reports.

Headlines to Watch Out For
  • Melanoma test adoption drives revenue growth
  • Barretts esophagus test expands market share
  • Atopic dermatitis test launch impacts future sales
  • Reimbursement policies affect profitability
  • Regulatory approvals influence product pipeline
Piotroski VR‑10 (Strict) 4.0
Net Income: -24.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.98 > 1.0
NWC/Revenue: 84.95% < 20% (prev 93.58%; Δ -8.63% < -1%)
CFO/TA 0.11 > 3% & CFO 64.3m > Net Income -24.2m
Net Debt (-262.6m) to EBITDA (13.1m): -19.99 < 3
Current Ratio: 5.26 > 1.5 & < 3
Outstanding Shares: last quarter (29.3m) vs 12m ago -2.87% < -2%
Gross Margin: 68.66% > 18% (prev 0.82%; Δ 6.78k% > 0.5%)
Asset Turnover: 62.03% > 50% (prev 62.51%; Δ -0.47% > 0%)
Interest Coverage Ratio: -342.5 > 6 (EBITDA TTM 13.1m / Interest Expense TTM 86.0k)
Altman Z'' -0.49
A: 0.51 (Total Current Assets 361.1m - Total Current Liabilities 68.7m) / Total Assets 578.6m
B: -0.39 (Retained Earnings -224.3m / Total Assets 578.6m)
C: -0.05 (EBIT TTM -29.5m / Avg Total Assets 554.9m)
D: -2.08 (Book Value of Equity -224.0m / Total Liabilities 107.7m)
Altman-Z'' Score: -0.49 = B
Beneish M -3.20
DSRI: 0.82 (Receivables 43.4m/51.2m, Revenue 344.2m/332.1m)
GMI: 1.19 (GM 68.66% / 81.87%)
AQI: 0.89 (AQ_t 0.18 / AQ_t-1 0.20)
SGI: 1.04 (Revenue 344.2m / 332.1m)
TATA: -0.15 (NI -24.2m - CFO 64.3m) / TA 578.6m)
Beneish M-Score: -3.20 (Cap -4..+1) = AA
What is the price of CSTL shares? As of April 11, 2026, the stock is trading at USD 23.13 with a total of 433,425 shares traded.
Over the past week, the price has changed by -6.47%, over one month by -13.05%, over three months by -41.68% and over the past year by +19.84%.
Is CSTL a buy, sell or hold? Castle Biosciences has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy CSTL.
  • StrongBuy: 8
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CSTL price?
Analysts Target Price 48.5 109.7%
Castle Biosciences (CSTL) - Fundamental Data Overview as of 06 April 2026
P/S = 2.1454
P/B = 1.5684
Revenue TTM = 344.2m USD
EBIT TTM = -29.5m USD
EBITDA TTM = 13.1m USD
Long Term Debt = 9.64m USD (from longTermDebt, last quarter)
Short Term Debt = 1.74m USD (from shortTermDebt, last quarter)
Debt = 36.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -262.6m USD (recalculated: Debt 36.9m - CCE 299.5m)
Enterprise Value = 475.9m USD (738.5m + Debt 36.9m - CCE 299.5m)
Interest Coverage Ratio = -342.5 (Ebit TTM -29.5m / Interest Expense TTM 86.0k)
EV/FCF = 16.80x (Enterprise Value 475.9m / FCF TTM 28.3m)
FCF Yield = 5.95% (FCF TTM 28.3m / Enterprise Value 475.9m)
FCF Margin = 8.23% (FCF TTM 28.3m / Revenue TTM 344.2m)
Net Margin = -7.02% (Net Income TTM -24.2m / Revenue TTM 344.2m)
Gross Margin = 68.66% ((Revenue TTM 344.2m - Cost of Revenue TTM 107.9m) / Revenue TTM)
Gross Margin QoQ = 36.59% (prev 77.48%)
Tobins Q-Ratio = 0.82 (Enterprise Value 475.9m / Total Assets 578.6m)
Interest Expense / Debt = 0.07% (Interest Expense 24.0k / Debt 36.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -23.3m (EBIT -29.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.26 (Total Current Assets 361.1m / Total Current Liabilities 68.7m)
Debt / Equity = 0.08 (Debt 36.9m / totalStockholderEquity, last quarter 470.9m)
Debt / EBITDA = -19.99 (Net Debt -262.6m / EBITDA 13.1m)
Debt / FCF = -9.27 (Net Debt -262.6m / FCF TTM 28.3m)
Total Stockholder Equity = 458.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.35% (Net Income -24.2m / Total Assets 578.6m)
RoE = -5.27% (Net Income TTM -24.2m / Total Stockholder Equity 458.4m)
RoCE = -6.29% (EBIT -29.5m / Capital Employed (Equity 458.4m + L.T.Debt 9.64m))
 RoIC = -4.97% (negative operating profit) (NOPAT -23.3m / Invested Capital 468.4m)
 WACC = 6.20% (E(738.5m)/V(775.4m) * Re(6.51%) + D(36.9m)/V(775.4m) * Rd(0.07%) * (1-Tc(0.21)))
Discount Rate = 6.51% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 3.95%
[DCF] Terminal Value 79.71% ; FCFF base≈31.6m ; Y1≈20.8m ; Y5≈9.49m
[DCF] Fair Price = 18.37 (EV 283.4m - Net Debt -262.6m = Equity 546.0m / Shares 29.7m; r=6.20% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 50.18 | EPS CAGR: 1.48% | SUE: 1.00 | # QB: 1
Revenue Correlation: 92.96 | Revenue CAGR: 36.82% | SUE: 1.27 | # QB: 4
EPS next Quarter (2026-06-30): EPS=-0.31 | Chg7d=+0.000 | Chg30d=+0.048 | Revisions Net=+3 | Analysts=8
EPS current Year (2026-12-31): EPS=-1.18 | Chg7d=+0.000 | Chg30d=+0.110 | Revisions Net=+3 | Growth EPS=-41.6% | Growth Revenue=+0.4%
EPS next Year (2027-12-31): EPS=-0.54 | Chg7d=+0.000 | Chg30d=+0.095 | Revisions Net=+1 | Growth EPS=+53.7% | Growth Revenue=+12.7%
[Analyst] Revisions Ratio: +0.60 (4 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle